news
Oncolytic adenovirus trial boosts pancreatic cancer survival
A new Phase 2b trial published in Nature Medicine shows intravenous hyaluronidase-expressing oncolytic adenovirus, combined with chemotherapy, significantly improved survival for metastatic pancreatic cancer patients. The treatment targeted the tumor microenvironment to make chemotherapy more effective. Researchers at the Princess Margaret Cancer Centre led the study with 103 patients.
A new Phase 2b trial published in Nature Medicine shows intravenous hyaluronidase-expressing oncolytic adenovirus, combined with chemotherapy, significantly improved survival for metastatic pancreatic cancer patients. The treatment targeted the tumor microenvironment to make chemotherapy more effective. Researchers at the Princess Margaret Cancer Centre led the study with 103 patients.
The architecture take
The cancer world is always looking for new ways to get the good stuff into tumors. This trial on metastatic pancreatic cancer, led by Dr. Renuka Iyer, is interesting because it uses an oncolytic virus — a virus engineered to infect and kill cancer cells — but also to break down the dense tumor matrix. It's like sending in a tiny demolition crew before the main attack. That hyaluronidase enzyme helps chew through the physical barrier around the tumor, making the chemotherapy agents more available to the cancer cells. It's a smart play to improve drug delivery and overall survival, from 10.9 months to 15.6 months. The point isn't that you'll be getting this tomorrow; it’s the continued shift toward therapies that don't just blast everything but instead re-engineer the tumor environment itself. More precise, less collateral damage. That's the direction of travel for systemic disease.